Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The last earnings update was 24 days ago. More info.
Add to Portfolio Compare Print
COPN Share Price and Events
7 Day Returns
1 Year Returns
COPN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Cosmo Pharmaceuticals (COPN) | 0.5% | 15.7% | 6.4% | -29.6% | -42.5% | -21.3% |
| CH Pharmaceuticals | -2.8% | -9.2% | -4.8% | 11.2% | 3.4% | 3.9% |
| CH Market | 0.7% | 1.1% | 5.1% | 2.9% | 12.7% | 12.6% |
1 Year Return vs Industry and Market
- COPN underperformed the Pharmaceuticals industry which returned 11.2% over the past year.
- COPN underperformed the Market in Switzerland which returned 2.9% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Cosmo Pharmaceuticals
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Cosmo Pharmaceuticals.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 5 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 9.5% |
| Perpetual Growth Rate | 10-Year CH Government Bond Rate | 3.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CH Govt Bond Rate | 3.3% |
| Equity Risk Premium | S&P Global | 7.1% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.73 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 12.5%) (12.94%)) |
0.873 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.87 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.873 * 7.14%) |
9.51% |
Discounted Cash Flow Calculation for SWX:COPN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Cosmo Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (EUR, Millions) | Source |
Present Value Discounted (@ 9.51%) |
|
|---|---|---|---|
| 2019 | -18.87 | Analyst x3 | -17.23 |
| 2020 | 26.50 | Analyst x2 | 22.10 |
| 2021 | 87.00 | Analyst x1 | 66.24 |
| 2022 | 192.00 | Analyst x1 | 133.49 |
| 2023 | 335.00 | Analyst x1 | 212.69 |
| 2024 | 465.64 | Est @ 39% | 269.95 |
| 2025 | 597.32 | Est @ 28.28% | 316.22 |
| 2026 | 721.43 | Est @ 20.78% | 348.75 |
| 2027 | 833.45 | Est @ 15.53% | 367.91 |
| 2028 | 932.23 | Est @ 11.85% | 375.77 |
| Present value of next 10 years cash flows | €2,095.91 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= €932.23 × (1 + 3.28%) ÷ (9.51% – 3.28%) |
€15,437.53 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= €15,437.53 ÷ (1 + 9.51%)10 |
€6,222.72 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= €2,095.91 + €6,222.72 |
€8,318.63 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €8,318.63 / 14.84 |
€560.72 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | EUR/CHF
(Reporting currency to currency of SWX:COPN) |
1.143 |
| Value per Share (CHF) |
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €560.72 x 1.143 |
CHF641.02 |
| Value per share (CHF) | From above. | CHF641.02 |
| Current discount | Discount to share price of
CHF94.20
= -1 x (CHF94.20 - CHF641.02) / CHF641.02 |
85.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Cosmo Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Cosmo Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in EUR | €-1.20 |
| SWX:COPN Share Price ** | SWX (2019-04-18) in CHF | CHF94.2 |
| SWX:COPN Share Price converted to EUR reporting currency | Exchange rate (CHF/ EUR) 0.875 | €82.4 |
| Europe Pharmaceuticals Industry PE Ratio | Median Figure of 44 Publicly-Listed Pharmaceuticals Companies | 21.68x |
| Switzerland Market PE Ratio | Median Figure of 174 Publicly-Listed Companies | 18.53x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Cosmo Pharmaceuticals.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = SWX:COPN Share Price ÷ EPS (both in EUR) = 82.4 ÷ -1.20 |
-68.66x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cosmo Pharmaceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
- Cosmo Pharmaceuticals is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does
Cosmo Pharmaceuticals's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -68.66x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
66.3%per year |
| Europe Pharmaceuticals Industry PEG Ratio | Median Figure of 35 Publicly-Listed Pharmaceuticals Companies | 1.78x |
| Switzerland Market PEG Ratio | Median Figure of 122 Publicly-Listed Companies | 2.35x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Cosmo Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Cosmo Pharmaceuticals's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in EUR | €29.91 |
| SWX:COPN Share Price * | SWX (2019-04-18) in CHF | CHF94.2 |
| SWX:COPN Share Price converted to EUR reporting currency | Exchange rate (CHF/ EUR) 0.875 | €82.4 |
| Switzerland Pharmaceuticals Industry PB Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 2.79x |
| Switzerland Market PB Ratio | Median Figure of 210 Publicly-Listed Companies | 1.71x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = SWX:COPN Share Price ÷ Book Value per Share (both in EUR) = 82.4 ÷ 29.91 |
2.75x |
* Primary Listing of Cosmo Pharmaceuticals.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Cosmo Pharmaceuticals is good value based on assets compared to the CH Pharmaceuticals industry average.
Value checks
We assess Cosmo Pharmaceuticals's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Cosmo Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
- Cosmo Pharmaceuticals's earnings growth is expected to exceed the Switzerland market average.
- Cosmo Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| SWX:COPN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | 66.3% |
| SWX:COPN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 35.8% |
| Switzerland Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 5% |
| Switzerland Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 2.2% |
| Switzerland Market Earnings Growth Rate | Market Cap Weighted Average | 9.5% |
| Switzerland Market Revenue Growth Rate | Market Cap Weighted Average | 3.5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 426 | 231 | 174 | 3 |
| 2022-12-31 | 270 | 113 | 103 | 4 |
| 2021-12-31 | 176 | 50 | 38 | 5 |
| 2020-12-31 | 119 | 18 | -2 | 5 |
| 2019-12-31 | 71 | -7 | -27 | 5 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 67 | -10 | -18 |
| 2018-09-30 | 70 | -11 | -20 |
| 2018-06-30 | 72 | -13 | -23 |
| 2018-03-31 | 70 | -11 | -28 |
| 2017-12-31 | 68 | -9 | -32 |
| 2017-09-30 | 68 | -6 | -18 |
| 2017-06-30 | 69 | -2 | -4 |
| 2017-03-31 | 69 | 10 | 8 |
| 2016-12-31 | 68 | 22 | 19 |
| 2016-09-30 | 70 | 18 | 18 |
| 2016-06-30 | 72 | 14 | 16 |
| 2016-03-31 | 66 | -13 | 132 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 11.22 | 17.70 | 7.00 | 3.00 |
| 2022-12-31 | 6.77 | 9.68 | 4.83 | 4.00 |
| 2021-12-31 | 2.16 | 4.48 | 0.88 | 4.00 |
| 2020-12-31 | 0.23 | 1.75 | -1.13 | 4.00 |
| 2019-12-31 | -1.80 | -1.40 | -2.12 | 4.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.20 |
| 2018-09-30 | -1.36 |
| 2018-06-30 | -1.53 |
| 2018-03-31 | -1.86 |
| 2017-12-31 | -2.19 |
| 2017-09-30 | -1.23 |
| 2017-06-30 | -0.25 |
| 2017-03-31 | 0.56 |
| 2016-12-31 | 1.37 |
| 2016-09-30 | 1.26 |
| 2016-06-30 | 1.15 |
| 2016-03-31 | 9.38 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Cosmo Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Future performance checks
We assess Cosmo Pharmaceuticals's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Cosmo Pharmaceuticals has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Cosmo Pharmaceuticals performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Cosmo Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Cosmo Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Cosmo Pharmaceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 66.50 | -18.01 | 50.64 | 10.39 |
| 2018-09-30 | 69.51 | -20.49 | 52.34 | 9.67 |
| 2018-06-30 | 72.42 | -22.97 | 54.03 | 8.95 |
| 2018-03-31 | 70.02 | -27.71 | 50.16 | 9.00 |
| 2017-12-31 | 67.71 | -32.45 | 46.28 | 9.05 |
| 2017-09-30 | 68.26 | -17.99 | 38.40 | 8.78 |
| 2017-06-30 | 68.81 | -3.53 | 30.52 | 8.51 |
| 2017-03-31 | 68.60 | 7.91 | 23.09 | 8.00 |
| 2016-12-31 | 68.39 | 19.34 | 15.66 | 7.49 |
| 2016-09-30 | 70.34 | 17.80 | 12.85 | 10.43 |
| 2016-06-30 | 72.28 | 16.26 | 10.04 | 13.36 |
| 2016-03-31 | 66.46 | 132.23 | 16.45 | 18.22 |
| 2015-12-31 | 60.63 | 248.19 | 22.87 | 23.08 |
| 2015-09-30 | 59.59 | 241.11 | 25.74 | 23.18 |
| 2015-06-30 | 58.55 | 234.04 | 28.60 | 23.27 |
| 2015-03-31 | 69.10 | 153.68 | 22.64 | 21.24 |
| 2014-12-31 | 79.64 | 73.32 | 16.67 | 19.22 |
| 2014-09-30 | 75.78 | 77.76 | 13.51 | 20.11 |
| 2014-06-30 | 71.91 | 82.20 | 10.35 | 21.01 |
| 2014-03-31 | 64.65 | 75.47 | 9.02 | 19.31 |
| 2013-12-31 | 57.39 | 68.73 | 7.69 | 17.60 |
| 2013-09-30 | 51.40 | 66.35 | 7.42 | 14.94 |
| 2013-06-30 | 45.41 | 63.96 | 7.15 | 12.27 |
| 2013-03-31 | 52.51 | 41.64 | 6.57 | 11.59 |
| 2012-12-31 | 59.60 | 19.32 | 5.98 | 10.92 |
| 2012-09-30 | 58.82 | 21.03 | 6.09 | 9.04 |
| 2012-06-30 | 58.05 | 22.72 | 6.21 | 7.16 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Cosmo Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Cosmo Pharmaceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Cosmo Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Cosmo Pharmaceuticals's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Cosmo Pharmaceuticals's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Cosmo Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
- Cosmo Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Cosmo Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 444.85 | 158.15 | 349.44 |
| 2018-09-30 | 444.85 | 158.15 | 349.44 |
| 2018-06-30 | 456.37 | 4.26 | 187.10 |
| 2018-03-31 | 456.37 | 4.26 | 187.10 |
| 2017-12-31 | 470.12 | 4.48 | 172.70 |
| 2017-09-30 | 470.12 | 4.48 | 172.70 |
| 2017-06-30 | 480.71 | 4.93 | 177.57 |
| 2017-03-31 | 480.71 | 4.93 | 177.57 |
| 2016-12-31 | 415.56 | 5.31 | 166.49 |
| 2016-09-30 | 415.56 | 5.31 | 166.49 |
| 2016-06-30 | 414.41 | 7.42 | 133.54 |
| 2016-03-31 | 414.41 | 7.42 | 133.54 |
| 2015-12-31 | 403.65 | 8.13 | 116.34 |
| 2015-09-30 | 403.65 | 8.13 | 116.34 |
| 2015-06-30 | 391.74 | 9.96 | 47.17 |
| 2015-03-31 | 391.74 | 9.96 | 47.17 |
| 2014-12-31 | 152.29 | 10.93 | 59.46 |
| 2014-09-30 | 152.29 | 10.93 | 59.46 |
| 2014-06-30 | 174.40 | 10.82 | 53.47 |
| 2014-03-31 | 174.40 | 10.82 | 53.47 |
| 2013-12-31 | 220.16 | 11.75 | 168.16 |
| 2013-09-30 | 220.16 | 11.75 | 168.16 |
| 2013-06-30 | 182.33 | 12.65 | 95.15 |
| 2013-03-31 | 182.33 | 12.65 | 95.15 |
| 2012-12-31 | 124.60 | 12.84 | 27.30 |
| 2012-09-30 | 124.60 | 12.84 | 27.30 |
| 2012-06-30 | 108.30 | 1.78 | 31.89 |
- Cosmo Pharmaceuticals's level of debt (35.6%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (5.3% vs 35.6% today).
- Operating cash flow is negative therefore debt is not well covered.
- Unable to confirm if the interest payments on Cosmo Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
Financial health checks
We assess Cosmo Pharmaceuticals's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CHF2,000 of
Cosmo Pharmaceuticals
shares you are expected to receive
CHF0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Cosmo Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Cosmo Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Europe Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 32 Stocks | 3.5% |
| Switzerland Market Average Dividend Yield | Market Cap Weighted Average of 167 Stocks | 3.1% |
| Switzerland Minimum Threshold Dividend Yield | 10th Percentile | 1.3% |
| Switzerland Bottom 25% Dividend Yield | 25th Percentile | 1.9% |
| Switzerland Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | 1.30 | 2.00 |
| 2022-12-31 | 0.73 | 3.00 |
| 2021-12-31 | 0.52 | 5.00 |
| 2020-12-31 | 0.30 | 5.00 |
| 2019-12-31 | 0.00 | 5.00 |
| Date (Data in €) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-03-29 | 0.000 | 0.000 |
| 2018-07-26 | 0.000 | 0.000 |
| 2017-05-26 | 1.500 | 1.258 |
| 2016-07-29 | 1.400 | 0.923 |
| 2014-03-27 | 1.000 | 0.748 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Cosmo Pharmaceuticals has not reported any payouts.
- Unable to verify if Cosmo Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Cosmo Pharmaceuticals's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Cosmo Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | €1,671,169 |
| AGE | 55 |
| TENURE AS CEO | 5.1 years |
CEO Bio
Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director since 2006. Mr. Chà served as a Senior Partner at Studio Legale Edoardo Ricci e Associati, Milan until March 27, 2014. He specialized in company law, mergers and acquisitions. He joined the Studio Legale Edoardo Ricci e Associati in 1988. He served as an Assistant of the Central Director for Corporate Matters of Fininvest Group from 1987 to 1988. He served as the Non-Executive Vice Chairman of Cosmo Pharmaceuticals N.V. He served as a Director of Santarus, Inc. from April 10, 2012 to January 2, 2014. He served as a Director of II.PP.A.B. Milan (ex-ECA), from 1994 to 1998 a charitable institution owning hospitals and specialized in elderly care. He is Lecturer in conferences and seminars held by universities and institutions on commercial and company law issues. Mr. Chà has a Degree in Law from the University of Milan (ITA) and an LL.M. from the University of Leicester (GBR) in European Union Commercial Law.
CEO Compensation
- Alessandro's compensation has been consistent with company performance over the past year.
- Alessandro's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure
Average tenure and age of the Cosmo Pharmaceuticals management team in years:
- The average tenure for the Cosmo Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Mauro Ajani
Founder & Chairman
63
13.3 yrs
Alessandro Della Chà
CEO & Executive Director
€2M
55
5.1 yrs
Giuseppe Cipriano
Chief Operating Officer
61
18.3 yrs
Luigi Moro
Chief Scientific Officer
67
19.6 yrs
Chris Tanner
Head of Transactions Office & Executive Director
€781K
67
2.9 yrs
Niall Donnelly
Chief Financial Officer
44
2.8 yrs
Davide Malavasi
Technical Director
45
7.6 yrs
John Manieri
Head of Investor Relations
Blake Boland
Chief Sales Officer
58
2.5 yrs
Massimo Pedrani
Head of Generics Business Development
64
Board of Directors Tenure
Average tenure and age of the Cosmo Pharmaceuticals board of directors in years:
- The average tenure for the Cosmo Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Mauro Ajani
Founder & Chairman
63
7 yrs
Alessandro Della Chà
CEO & Executive Director
€2M
55
13.3 yrs
Chris Tanner
Head of Transactions Office & Executive Director
€781K
67
13.3 yrs
Dieter Enkelmann
Non-Executive Director
€156K
59
13.3 yrs
Kevin Donovan
Non-Executive Director
€140K
59
3.1 yrs
Geert D’Haens
Member of Scientific Advisory Board
William Sandborn
Member of Scientific Advisory Board
Silvio Danese
Member of Scientific Advisory Board
Maria Roncarolo
Non-Executive Director
€156K
64
7 yrs
Ralf Kiesslich
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CHF) | Value (CHF) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Cosmo Pharmaceuticals's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Cosmo Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Should Cosmo Pharmaceuticals N.V. (VTX:COPN) Be Your Next Stock Pick?
(VTX:COPN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of COPN, it
Simply Wall St - – Full articleCould Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Investor Composition Influence The Stock Price?
Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that used to be publicly owned tend to have lower insider ownership. … institutions own shares in the company.
Simply Wall St - – Full articleDoes Cosmo Pharmaceuticals N.V.'s (VTX:COPN) CEO Salary Compare Well With Others?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Alessandro Della Chà's Compensation Compare With Similar Sized Companies. … has a market capitalization of CHF1.3b, and pays its CEO total annual compensation worth €1.7m.
Simply Wall St - – Full articleHow Much Of Cosmo Pharmaceuticals NV (VTX:COPN) Do Institutions Own?
The big shareholder groups in Cosmo Pharmaceuticals NV (VTX:COPN) have power over the company. … Cosmo Pharmaceuticals isn't enormous, but it's not particularly small either. … Taking a look at the our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleBreaking Down Cosmo Pharmaceuticals NV's (VTX:COPN) Ownership Structure
In this article, I will take a quick look at Cosmo Pharmaceuticals NV’s (VTX:COPN) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine COPN's ownership structure in more detail.
Simply Wall St - – Full articleYou Should Consider Cosmo Pharmaceuticals NV (VTX:COPN) Because Of These Reasons
Cosmo Pharmaceuticals NV (VTX:COPN) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of COPN, it
Simply Wall St - – Full articleBreaking Down Cosmo Pharmaceuticals NV.'s (VTX:COPN) Ownership Structure
With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in COPN should also look at another important group of investors: private companies, with a stake of 45.08%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.
Simply Wall St - – Full articleCan Cosmo Pharmaceuticals NV. (VTX:COPN) Improve Your Portfolio Returns?
Generally, an investor should consider two types of risk that impact the market value of COPN. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, COPN appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.
Simply Wall St - – Full articleShould You Buy Cosmo Pharmaceuticals NV. (VTX:COPN)?
Let’s take a look at Cosmo Pharmaceuticals’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price.
Simply Wall St - – Full articleWhere Cosmo Pharmaceuticals NV.'s (VTX:COPN) Earnings Growth Stands Against Its Industry
Today I will examine Cosmo Pharmaceuticals NV.'s (SWX:COPN) latest earnings update (30 June 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of COPN's industry performed. … View our latest analysis for Cosmo Pharmaceuticals How Did COPN's Recent Performance Stack Up Against Its Past? … For Cosmo Pharmaceuticals, its latest earnings (trailing twelve month) is -€3.53M, which, against the prior year's figure, has turned from positive to negative.
Simply Wall St - – Full articleCompany Info
Description
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon. The company also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous lesion detection during colonoscopies; and Aemcolo, a pharmaceutical product used for the treatment of bacterial infections of the colon, such as traveler’s diarrhea, infectious colitis, clostridium difficile associated disease, and diverticulitis, as well as for treatment of inflammatory bowel diseases and hepatic encephalopathy. In addition, it offers Qolotag, a medical device that enhances the detection of lesions during sigmoidoscopies; Remimazolam, an ultra-short-acting sedative/anesthetic. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Details
| Name: | Cosmo Pharmaceuticals N.V. |
| COPN | |
| Exchange: | SWX |
| Founded: | 1997 |
| CHF1,397,524,164 | |
| 14,835,713 | |
| Website: | http://www.cosmopharma.com |
| Address: |
Cosmo Pharmaceuticals N.V. Riverside II, Sir John Rogerson’s Quay, Dublin, Co. Dublin, 2, Ireland |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| SWX | COPN | New Common Shares | SIX Swiss Exchange | CH | CHF | 09. Mar 2007 | |
| OTCPK | CMOP.F | New Common Shares | Pink Sheets LLC | US | USD | 09. Mar 2007 | |
| DB | C43 | New Common Shares | Deutsche Boerse AG | DE | EUR | 09. Mar 2007 | |
| LSE | 0RGI | New Common Shares | London Stock Exchange | GB | CHF | 09. Mar 2007 | |
| BATS-CHIXE | COPNZ | New Common Shares | BATS 'Chi-X Europe' | GB | CHF | 09. Mar 2007 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/22 21:13 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/17 |
| Last earnings filing: | 2019/03/29 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
